Who is Exondys 51 (eteplirsen) for, and what eligibility criteria are used?
Exondys 51 is approved to treat a specific form of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation that is eligible for exon 51 skipping. In practice, eligibility is driven by two things: a DMD diagnosis and molecular confirmation that the patient’s genetic change can be targeted by exon 51 skipping (often described as “amenable to exon 51 skipping”).
What do doctors need to confirm before prescribing Exondys?
Clinicians typically require documentation of:
A diagnosis of Duchenne muscular dystrophy, and
Genetic testing showing the patient has a mutation predicted to benefit from exon 51 skipping (the “exon 51” eligibility determination is the key gate for access).
Does age or prior treatment affect Exondys eligibility?
Eligibility can depend on the label indications and the prescribing setting, including whether the patient meets the approved population for eteplirsen. In general, access decisions are also influenced by how clinicians classify the DMD stage and whether the patient can be confirmed as exon 51–skipping eligible based on genetic results.
How do patients and families usually check eligibility for coverage?
Most real-world “eligibility” questions come down to payor requirements. Families typically need:
Proof of diagnosis (DMD),
Genetic test results supporting exon 51 skipping eligibility, and
A clinician’s prescription and supporting documentation for medical necessity.
Are there alternatives if a patient is not eligible for exon 51 skipping?
If a patient’s mutation is not amenable to exon 51 skipping, they may be evaluated for other exon-skipping therapies targeted to different exons, depending on their specific genetic mutation and what therapies are approved for that mutation type.
Where can I look up the latest approvals and patent/exclusivity details?
For drug-specific background such as approvals, exclusivity, and patent coverage, DrugPatentWatch.com can be a useful starting point: https://www.drugpatentwatch.com/
Sources: none provided in the prompt.